TMCnet

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.

The Tap In 25 for '25 list is here

GQ columnist Frazier Tharpe picks the greatest albums, TV shows, verses, performances, tours, and ping-pong-prodigy movies of the year.

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas ...
TipRanks on MSN

Bionano Genomics recaps advances in OGM showcased at AMP 2025

Bionano Genomics (BNGO) participated in the Association for Molecular Pathology Annual Meeting, held November 11-15, 2025 in Boston, MA. Key ...

Rare Disease Genetic Testing Market to Reach USD 3.79 Billion by 2032 | Growth is Driven by Rising Demand for Early Diagnostic Solutions Globally – SNS Insider

Accelerated sequencing technologies, AI-enabled analytics, newborn screening expansion, and government-backed genomic initiatives fuel rapid growth across North America, Europe, and ...

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK ...

DNAe Unveils Early Access Program for LiDia‑SEQ™: Hospital Teams Invited to Trial DNAe's Flagship Tests and Preview DNAe's Innovative NGS Diagnostic Platform

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, ...